Skip to main content

Rheumatology Grand Rounds: Future directions in osteoporosis therapy; integrating osteoanabolic agents and senescence-targeted strategies

College of Medicine - Tucson, Division of Rheumatology

When

March 13, 2026, 9 – 10 a.m.

Where 

Join virtually

Event Description

Joshua N. Farr, PhD, will be presenting at Rheumatology Grand Rounds on Friday, March 13. Dr. Farr is an associate professor with the University of Arizona Department of Medicine in the Rheumatology Division and is the Ethel McChesney Chair for Osteoporosis Research at the University of Arizona Arthritis Center. The title of the presentation is "Future Directions in Osteoporosis Therapy: Integrating Osteoanabolic Agents and Senescence-Targeted Strategies.”

Learning Objectives: Participants should be able to:

  1. Describe the mechanisms and clinical evidence supporting osteoanabolic therapies for osteoporosis, including romosozumab and other anabolic agents.
  2. Explain how skeletal aging and cellular senescence influence bone remodeling and therapeutic response.
  3. Evaluate emerging strategies that integrate osteoanabolic therapies with senescence-targeted approaches to improve durability of osteoporosis treatment.

Target Audience: Physicians and other health care providers

Methodology: Grand Rounds lecture

Accreditation Statement:

The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Arizona College of Medicine – Tucson designates this live activity for a maximum of one AMA PRA Category 1 credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Relevant Financial Relationships Statement(s):

University of Arizona Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Presenter Details

Joshua N. Farr, PhD

Associate Professor

Ethel McChesney Chair for Osteoporosis Research

University of Arizona, Department of Medicine

Division of Rheumatology

The University of Arizona Arthritis Center